Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.

Schizophrenia research - 1 Feb 2014

Miura Itaru, Zhang Jian-Ping, Nitta Masahiro, Lencz Todd, Kane John M, Malhotra Anil K, Yabe Hirooki, Correll Christoph U

Abstract excerpt

BACKGROUND: Tardive dyskinesia (TD) is a serious long-term consequence of antipsychotic treatment. Since brain-derived neurotrophic factor (BDNF) has potent neurotrophic activity, genetic alterations in the BDNF gene may affect antipsychotic-induced TD. METHODS: Searching PubMed and Web of Science until 05/31/13, we conducted a systematic review and a meta-analysis of the effects of BDNF Val66Met polymorphism on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Brain-Derived Neurotrophic Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Databases, Bibliographic

Share to Methionine

Share to Movement Disorders

Share to Schizophrenia

Share to Severity of Illness Index

Share to Valine

Source

Open in PubMed Open full text

Identifiers

PMID: 24411528
DOI: 10.1016/j.schres.2013.12.011
PMCID: PMC4010225

Genes

BDNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.PMID 24411528Read ↗

No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.Semantic proximity Read ↗

Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba.Semantic proximity Read ↗

BDNF Val66Met and clinical response to antipsychotic drugs: A systematic review and meta-analysis.Semantic proximity Read ↗

Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients.Semantic proximity Read ↗

BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis.Semantic proximity Read ↗

Effects of antipsychotics on the BDNF in schizophrenia.Semantic proximity Read ↗

Tardive Dyskinesia Development, Superoxide Dismutase Levels, and Relevant Genetic PolymorphismsSemantic proximity Read ↗

BDNF polymorphisms across the spectrum of psychiatric morbidity: A protocol for a systematic review and meta-analysis.Semantic proximity Read ↗

Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia.Semantic proximity Read ↗

Pharmacogenetics of tardive dyskinesia: an updated review of the literature.Semantic proximity Read ↗

Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.Semantic proximity Read ↗

Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.